Research programme: oligodendrocyte transcription factor-2 inhibitors - Curtana Pharmaceuticals

Drug Profile

Research programme: oligodendrocyte transcription factor-2 inhibitors - Curtana Pharmaceuticals

Alternative Names: CT-179; OLIG2 inhibitors - Curtana Pharmaceuticals

Latest Information Update: 21 Apr 2016

Price : $50

At a glance

  • Originator Curtana Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Glioblastoma

Most Recent Events

  • 20 Apr 2016 Preclinical trials in Glioblastoma in United Kingdom (PO)
  • 01 Oct 2014 Curtana pharmaceuticals receives Small Business Technology Transfer grant from NIH for the development OLIG2 inhibitors for the treatment of Glioblastoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top